1-3 of 3
Hans Peter Hartung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Natalizumab Increases Circulating CD34+ Cells with An Impaired Functional Potential In Patients with Multiple Sclerosis without Affecting the Bone Marrow.

Christian Saure, MD, Fabian Zohren, MD, Thomas Schroeder, MD, Ingmar Bruns, MD, Ron Patrick Cadeddu, Ute Fischer, MD, Guido Kobbe, MD, Hans Peter Hartung, Bernd C Kieseier, Rainer Haas
Journal: Blood
Blood (2010) 116 (21): 2620.
https://doi.org/10.1182/blood.V116.21.2620.2620
Published: 2010
Journal Articles

The monoclonal anti–VLA-4 antibody natalizumab mobilizes CD34 + hematopoietic progenitor cells in humans

Brief Report
Fabian Zohren, Diamandis Toutzaris, Viola Klärner, Hans-Peter Hartung, Bernd Kieseier, Rainer Haas
Journal: Blood
Blood (2008) 111 (7): 3893–3895.
https://doi.org/10.1182/blood-2007-10-120329
Published: 2008
Journal Articles

Treatment with Natalizumab in Patients with Multiple Sclerosis Is Associated with Increased Numbers of Circulating CD34+ Cells in the Peripheral Blood.

Fabian Zohren, MD, Akos Czibere, MD, Diamandis Toutzaris, MD, Hans-Peter Hartung, MD, Ingmar Bruns, MD, Rainer Haas, MD
Journal: Blood
Blood (2007) 110 (11): 4916.
https://doi.org/10.1182/blood.V110.11.4916.4916
Published: 2007